Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VERA Vera Therapeutics
8.740-0.400-4.38%
Close
01/27 16:00 ET
8.550-0.190-2.17%
Post Mkt Price 01/27 19:58 ET
High
9.510
Open
9.150
Turnover
4.31M
Low
8.480
Pre Close
9.140
Volume
492.85K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer
Seasoned Commercial Operations Executive Positions Company for Next Stage of Growth Innocoll Holdings Ltd. ("IHL"), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital ("GPC"), today
Vera Therapeutics to Host KOL Webinar on Atacicept
Why Vera Therapeutics Stock Bolted Higher This Week
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Vera Therapeutics, Inc. (VERA) Investigation
Vera Therapeutics (NASDAQ:VERA) Downgraded to "Hold" at Jefferies Financial Group
Jefferies Financial Group cut shares of Vera Therapeutics (NASDAQ:VERA – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, MarketBeat reports
HC Wainwright Comments on Vera Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:VERA)
Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Vera Therapeutics in a research report issue
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
Company Overview
More
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
CEO： Dr. Marshall Fordyce, M.D.
Market： NASDAQ
Listing Date： 05/14/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet